Confirm DM1 or DM2 genetically before building the care plan
DM1 and DM2 have overlapping but distinct patterns. A specialist review should verify the molecular report and clinical phenotype rather than use 'myotonia' or 'muscular dystrophy' as sufficient labels.
- DM1 molecular report showing the DMPK CTG-repeat expansion
- DM2 molecular report showing the CNBP/ZNF9 CCTG-repeat expansion
- Age at onset and pattern of weakness
- Myotonia, pain and functional limitations
- Family history and previous genetic counseling
- Cardiac, respiratory, sleep and swallowing history
DM1 and DM2 are multisystem disorders
The German Society for Muscular Diseases describes myotonic dystrophy as a multisystem disease. In addition to weakness and myotonia, patients may develop cardiac rhythm or conduction abnormalities, cataracts, swallowing problems, daytime sleepiness or sleep apnea, endocrine/metabolic disorders and gastrointestinal symptoms. A second opinion should therefore review the whole surveillance plan, not only muscle strength.
Cardiac surveillance is one of the highest-priority safety issues
DM1 and DM2 can involve the cardiac conduction system and myocardium. DGM materials emphasize regular ECG-based surveillance, and Charité has a cardiology pathway specifically for muscular dystrophies with cardiac involvement including DM1 and DM2. Depending on history and findings, assessment can include resting ECG, Holter monitoring, echocardiography and selected advanced cardiac testing.
- Resting ECG and interval comparison
- Holter or other prolonged rhythm monitoring when indicated
- Echocardiography and/or cardiac MRI when clinically relevant
- Review of syncope, palpitations or exertional symptoms
- Assessment of any pacemaker or ICD already in place
Respiratory and sleep assessment can explain fatigue and daytime sleepiness
Respiratory-muscle weakness, ineffective cough, sleep-disordered breathing and central hypersomnolence can all occur in myotonic dystrophy. Evaluation can include pulmonary-function testing, respiratory-muscle strength, nocturnal oximetry or sleep studies and review for non-invasive ventilation or cough-assist support where needed.
Swallowing and aspiration risk should be assessed when symptoms are present
Pharyngeal weakness and delayed swallowing can contribute to choking, aspiration and recurrent respiratory infections. Speech/swallowing assessment and nutrition review are appropriate when there is coughing during meals, weight loss, recurrent chest infections or prolonged mealtimes.
Myotonia can be treated symptomatically, but cardiac context matters
DGM materials describe antimyotonic drug options for significant stiffness, while also stressing cardiac surveillance because several agents can affect conduction. Medication choice should therefore be made by a neuromuscular specialist with the patient's ECG and cardiac history available rather than self-directed from a drug list.
Cataract and endocrine/metabolic screening are part of routine care
Myotonic dystrophy can be associated with cataracts, diabetes or insulin resistance, thyroid and gonadal/endocrine abnormalities. Ophthalmology and targeted laboratory/endocrine follow-up may therefore be part of the long-term plan even when muscle symptoms are relatively stable.
Rehabilitation aims to preserve function and participation
There is no established medication that reverses the underlying muscle weakness in DM1 or DM2. Physiotherapy, occupational therapy, orthotics, mobility aids and individualized exercise can help maintain function, reduce secondary complications and adapt work or daily activities.
Anesthesia requires advance planning
DGM anesthesia guidance for DM1 highlights risks related to respiratory weakness, aspiration, cardiac conduction disease and sensitivity to respiratory-depressant drugs. Planned surgery or sedation should therefore include a clear anesthesia alert, current cardiopulmonary information and a postoperative monitoring plan. Acute breathing problems after sedation or surgery require local emergency care.
What to send for a German DM1/DM2 second opinion
A useful review depends on the molecular diagnosis and evidence of multisystem follow-up.
- DM1 or DM2 genetic report
- Neuromuscular specialist reports and EMG if performed
- Recent ECG, Holter and echocardiography/cardiac MRI reports
- Pulmonary-function and sleep-study results
- Swallowing/nutrition reports when relevant
- Ophthalmology and endocrine/metabolic results
- Current medication list including antimyotonic or cardiac drugs
- Previous anesthesia complications or upcoming surgery details
- Physiotherapy, orthotic and mobility-assessment reports
- A specific question: diagnosis confirmation, cardiac/respiratory surveillance review, symptom management, surgery planning or multidisciplinary follow-up
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Myotonic Dystrophy Type 1 and 2 — German Society for Muscular Diseases (DGM) ↗
- Myotonic dystrophy anesthesia guidance — German Society for Muscular Diseases (DGM) ↗
- Neuromuscular diseases / muscle clinic — Charité – Universitätsmedizin Berlin ↗
- Cardiology for muscular dystrophies with cardiac involvement — Charité – Universitätsmedizin Berlin ↗
- Neuromuscular outpatient clinic — Heidelberg University Hospital ↗
- Neuromuscular outpatient clinic — University Medical Center Freiburg ↗
- Freiburg Neuromuscular Center — University Medical Center Freiburg ↗